Analysts Set Mast Therapeutics Inc (MSTX) Target Price at $1.70
Shares of Mast Therapeutics Inc (NYSE:MSTX) have received an average rating of “Hold” from the seven ratings firms that are presently covering the company. Four equities research analysts have rated the stock with a hold rating and two have assigned a buy rating to the company. The average 12-month price target among brokers that have covered the stock in the last year is $1.70.
Several equities research analysts have recently commented on the stock. S&P Equity Research boosted their target price on shares of Mast Therapeutics from $0.08 to $0.09 in a research report on Friday, October 14th. Maxim Group set a $5.00 target price on shares of Mast Therapeutics and gave the stock a “buy” rating in a research report on Monday, August 8th. Roth Capital reissued a “buy” rating and set a $2.00 target price on shares of Mast Therapeutics in a research report on Monday, August 1st. Canaccord Genuity reissued a “buy” rating and set a $3.00 target price on shares of Mast Therapeutics in a research report on Thursday, July 28th. Finally, Zacks Investment Research raised shares of Mast Therapeutics from a “sell” rating to a “buy” rating and set a $0.25 target price for the company in a research report on Friday, September 23rd.
Shares of Mast Therapeutics (NYSE:MSTX) opened at 0.0927 on Monday. Mast Therapeutics has a 52 week low of $0.07 and a 52 week high of $0.71. The company has a 50-day moving average of $0.08 and a 200 day moving average of $0.31. The firm’s market capitalization is $22.08 million.
Mast Therapeutics (NYSE:MSTX) last posted its quarterly earnings results on Tuesday, November 8th. The company reported ($0.04) earnings per share for the quarter, beating the consensus estimate of ($0.05) by $0.01. Equities research analysts anticipate that Mast Therapeutics will post ($0.19) earnings per share for the current year.
Mast Therapeutics Company Profile
Mast Therapeutics, Inc is a biopharmaceutical company. The Company develops clinical-stage therapies for serious or life-threatening diseases with unmet needs. The Company focuses on developing new therapies for sickle cell disease, a chronic and genetic disorder classified as a rare, or orphan, disease in the United States of America and European Union, and for heart failure, a condition with an unmet need for treatment options.
Receive News & Stock Ratings for Mast Therapeutics Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Mast Therapeutics Inc and related stocks with our FREE daily email newsletter.